scholarly journals Growing impact of pharmacogenomic on drug development and personalized medicine

2008 ◽  
Vol 9 (4) ◽  
pp. 171-172
Author(s):  
Mario Eandi
Keyword(s):  
Personalized Medicine ◽  
Drug Development ◽  
And Personalized Medicine

scholarly journals A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Simon Plummer ◽  
Stephanie Wallace ◽  
Graeme Ball ◽  
Roslyn Lloyd ◽  
Paula Schiapparelli ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Drug Development ◽  
Cancer Cells ◽  
Brain Cancer ◽  
Study Drug ◽  
Human Ipsc ◽  
And Personalized Medicine

scholarly journals Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine

2015 ◽  
Vol 1 (7) ◽  
pp. e1500439 ◽  
Author(s):  
Dean Ho ◽  
Chung-Huei Katherine Wang ◽  
Edward Kai-Hua Chow
Keyword(s):  
Personalized Medicine ◽  
Drug Development ◽  
Cancer Treatment ◽  
Nucleic Acid Delivery ◽  
Development Platform ◽  
Single Compound ◽  
The Many ◽  
Preclinical And Clinical Studies ◽  
And Personalized Medicine ◽  
Unique Chemical

The implementation of nanomedicine in cellular, preclinical, and clinical studies has led to exciting advances ranging from fundamental to translational, particularly in the field of cancer. Many of the current barriers in cancer treatment are being successfully addressed using nanotechnology-modified compounds. These barriers include drug resistance leading to suboptimal intratumoral retention, poor circulation times resulting in decreased efficacy, and off-target toxicity, among others. The first clinical nanomedicine advances to overcome these issues were based on monotherapy, where small-molecule and nucleic acid delivery demonstrated substantial improvements over unmodified drug administration. Recent preclinical studies have shown that combination nanotherapies, composed of either multiple classes of nanomaterials or a single nanoplatform functionalized with several therapeutic agents, can image and treat tumors with improved efficacy over single-compound delivery. Among the many promising nanomaterials that are being developed, nanodiamonds have received increasing attention because of the unique chemical-mechanical properties on their faceted surfaces. More recently, nanodiamond-based drug delivery has been included in the rational and systematic design of optimal therapeutic combinations using an implicitly de-risked drug development platform technology, termed Phenotypic Personalized Medicine–Drug Development (PPM-DD). The application of PPM-DD to rapidly identify globally optimized drug combinations successfully addressed a pervasive challenge confronting all aspects of drug development, both nano and non-nano. This review will examine various nanomaterials and the use of PPM-DD to optimize the efficacy and safety of current and future cancer treatment. How this platform can accelerate combinatorial nanomedicine and the broader pharmaceutical industry toward unprecedented clinical impact will also be discussed.

Sign in / Sign up

Export Citation Format

Share Document